Consequently, aberrant GGT expression is observed in various types of cancer, including ovarian (55), renal cell (56), lung (57), stomach (58) and pancreatic cancer (59)
(See Discontinuance of Therapy under Cautions.) Closely monitor for notable changes in behavior that could indicate emergence or worsening of suicidal thoughts or behavior or depression
Ongoing communication between patients and healthcare providers is essential to monitor symptom severity, weight changes, glycemic control, and treatment tolerability
10.1172/JCI26373 74
R., Melideo, S
Who Qualifies GLP-1 medications for weight management are appropriate for adults who meet the following criteria: BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related condition (high blood pressure, type 2 diabetes, high cholesterol, sleep apnea) Who should not take GLP-1 medications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) History of pancreatitis Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease) Pregnancy or planning to become pregnant Known hypersensitivity to semaglutide, tirzepatide, or any component of the formulation Your physician will review your full medical history, screen for contraindications, and assess your relationship with food and body image before prescribing
